Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Esmolol in acute ischemic syndromes.

Rita G Mitchell1, Marcus F Stoddard, Ori Ben-Yehuda

  • 1St Louis University Health Sciences Center, St Louis, Mo 63110-1250, USA.

American Heart Journal
|November 8, 2002
PubMed
Summary

Esmolol, an ultra-short-acting beta-blocker, may be a safe alternative for acute coronary syndrome patients with contraindications to standard beta-blockers. Safety events resolved upon discontinuation, suggesting potential benefits needing further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.

JACC. Advances·2026
Same author

Accelerating Testosterone Prescribing for U.S. Women: Implications for Cardiovascular Safety.

JACC. Advances·2026
Same author

Tricuspid Valve Academic Research Consortium-2 (TVARC-2): Trial Design and Endpoints

Journal of the American College of Cardiology·2026
Same author

Deep learning enables fully automated cineCT-based assessment of regional right ventricular function.

European heart journal. Imaging methods and practice·2026
Same author

Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.

Circulation·2026

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers reduce morbidity and mortality in acute coronary syndromes.
  • Potential side effects limit beta-blocker use in some patients.
  • Ultra-short-acting intravenous beta-blockers may offer benefits with fewer complications.

Purpose of the Study:

  • To evaluate the efficacy and safety of esmolol in patients with acute coronary syndromes and relative contraindications to beta-blocker therapy.
  • To compare esmolol infusion with standard therapy in a prospective randomized trial.

Main Methods:

  • 108 patients with acute coronary syndromes and contraindications received intravenous esmolol or standard therapy.
  • Follow-up was for 6 weeks, assessing primary efficacy outcomes (death, myocardial infarction, ischemia, arrhythmia, silent ischemia) and safety endpoints (hypotension, bradyarrhythmias, heart failure, bronchospasm).

Related Experiment Videos

Main Results:

  • Primary endpoint event rates were similar between esmolol and standard care groups.
  • Transient hypotension occurred more frequently with esmolol but resolved upon discontinuation.
  • No significant differences were observed in other safety endpoints like bradycardia, heart failure, bronchospasm, or heart block.

Conclusions:

  • Esmolol may serve as an alternative beta-blocker for patients with contraindications to standard therapy.
  • Safety events during esmolol administration were transient and resolved upon dose reduction or discontinuation.
  • Further research is required to confirm the safety and efficacy of esmolol in this patient population.